PLSE News

The past week saw four IPOs produce insignificant returns. All four deals finished the week at or above the offer price, but none gained more than 5%. The first bank IPO of 2016, Argentina-based Grupo Supervielle dual listed in New York and Buenos Aires; its $281 million IPO raised more than the other three small health care deals combined.  ...read more

Pulse Biosciences, which is developing treatments for solid tumors based on pulsed electric fields, raised $20 million by offering 5 million shares at $4, as expected. At $4 per share, Pulse commands a diluted market cap of $51 million. NovoCure (NVCR), which markets a wearable electric field device for brain cancer, raised $165 million at a $2.1 billion...read more

Pulse Biosciences, which is developing treatments for solid tumors based on pulsed electric fields, filed and ster terms for its IPO on Tuesday. The Burlingame, CA-based company plans to raise $20 million by offering 5.0 million shares at a price range of $4. At that price, Pulse Biosciences would command a fully diluted market value of $51 million.  The Burlingame,...read more